Life sciences news
-
Galapagos announces completion of patient enrollment for DIVERSITY Phase 3 study with filgotinib in Crohn’s Disease
Monday October 4th 2021
Read more
-
Sequana Medical announces FDA approval to expand patient enrolment in North American pivotal alfapump® study (POSEIDON)
Monday October 4th 2021
Read more
-
ExeVir announces first patient enrolled in phase 1b/2 clinical study evaluating XVR011 as antiviral treatment of patients hospitalised for COVID-19
Wednesday September 1st 2021
Read more
-
Publication of Positive Phase 1 Clinical Data evaluating THR-687 for Treatment of DME in Ophthalmology Science
Tuesday August 17th 2021
Read more
-
Galapagos reports positive topline results with selective TYK2 inhibitor GLPG3667 in Phase 1b psoriasis study
Thursday July 15th 2021
Read more
-
Galapagos demonstrates early clinical activity with SIK2/3 inhibition in inflammation
Thursday July 15th 2021
Read more
-
Galapagos announces new data supporting rapid symptom improvement and sustained steroid-free remission with filgotinib in patients with Ulcerative Colitis
Monday July 12th 2021
Read more
-
imec’s ultrasound sensor technology yields accurate pulse wave velocity and blood pressure values
Tuesday June 29th 2021
Read more
-
Become a flanders.bio member
Your news here?
-
OXURION completes patient enrollment for Part A of Phase 2 study evaluating THR-149 for treatment of Diabetic Macular Edema (DME)
Tuesday June 8th 2021
Read more
-
Sequana Medical announces first patient enrolled in SAHARA DESERT
Tuesday June 1st 2021
Read more
-
Mithra announces European approval of Estelle®
Friday May 21st 2021
Read more
More info?
Contact us
Ellen Telleir
Communication Coordinator
